Organization | German CML Study Group

German CML Study Group Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

1995

NCT00002771

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

1995

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (8)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

autologous bone marrow (1 trial)

busulfan (myleran) (1 trial)

cytarabine (cytosar-u) (1 trial)

hydroxyurea (hydrea) (1 trial)

idarubicin (idamycin) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

peripheral blood hematopoietic cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial APIs: 8